Caroline Liu

Caroline Liu

Auto-generated profile, based on publicly available information

Caroline Liu

Department of Otolaryngology‐Head and Neck Surgery University of Nevada Las Vegas Nevada USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CLCaroline Liu
Caroline Liu
NDNeha Debnath
Neha Debnath
GMGohar Mosoyan
Gohar Mosoyan
Kinsuk ChauhanKinsuk Chauhan
Kinsuk Chauhan
GVGeorge Vasquez-Rios
George Vasquez-Rios
SCSteven G. Coca
Steven G. Coca
Background: Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity. Methods: In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis. Results: After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies). Conclusions: Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.

12 December 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CLCaroline Liu
Caroline Liu
Sami AlasfarSami Alasfar
Sami Alasfar
PRPeter P. Reese
Peter P. Reese
SMSumit Mohan
Sumit Mohan
MDMona D. Doshi
Mona D. Doshi
CPChirag R. Parikh
Chirag R. Parikh
Kidney allocation trends from deceased donors with acute kidney injury (AKI) have not been characterized since initial kidney donor profile index (KDPI) reporting in 2012 and its use under the revised kidney allocation system (KAS) in 2014. We conducted a retrospective analysis of U.S. registry data to characterize kidney procurement and discard trends in deceased donors with AKI, defined by ≥50% or ≥0.3 mg/dL (≥4.0 mg/dL or ≥200% for stage 3) increase in terminal serum creatinine from admission. From 2010 to 2020, 172,410 kidneys were procured from 93,341 deceased donors 16 years or older. 34,984 kidneys were discarded (17,559 from AKI donors). The proportion of stage 3 AKI donors doubled from 6% (412/6841) in 2010 to 12% (1365/11493) in 2020. Procurement of stage 3 AKI kidneys increased from 51% (423/824) to 80% (2183/2730). While discard of stage 3 AKI kidneys increased from 41% (175/423) in 2010 to 44% (960/2183) in 2020, this increase was not statistically significant in interrupted time-series analysis following KAS implementation (slope difference -0.41 (-3.22, 2.4), and level change 3.09 (-6.4, 12.6)). In conclusion, the absolute number of stage 3 AKI kidneys transplanted has increased. Ongoing high discard rates of these kidneys suggest opportunities for improved utilization.